Resolvin D2 limits atherosclerosis progression via myeloid cell-GPR18.
atherosclerosis
inflammation
macrophage
myeloid
resolution
resolvin
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
31 Mar 2024
31 Mar 2024
Historique:
revised:
21
02
2024
received:
13
11
2023
accepted:
28
02
2024
medline:
19
3
2024
pubmed:
19
3
2024
entrez:
18
3
2024
Statut:
ppublish
Résumé
Dysregulated inflammation-resolution programs are associated with atherosclerosis progression. Resolvins, in part, mediate inflammation-resolution programs. Indeed, Resolvin D2 (RvD2) activates GPR18, a G-protein-coupled receptor, and limits plaque progression, though the cellular targets of RvD2 remain unknown. Here, we developed a humanized GPR18 floxed ("fl/fl") and a myeloid (Lysozyme M Cre) GPR18 knockout (mKO) mouse. We functionally validated this model by assessing efferocytosis in bone marrow-derived macrophages (BMDMs) and found that RvD2 enhanced efferocytosis in the fl/fl, but not in the mKO BMDMs. To understand the functions of RvD2-GPR18 in atherosclerosis, we performed a bone marrow transfer of fl/fl or mKO bone marrow into Ldlr
Identifiants
pubmed: 38498346
doi: 10.1096/fj.202302336RR
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23555Subventions
Organisme : HHS | NIH | NHLBI | Division of Intramural Research (DIR)
ID : HL141127
Organisme : HHS | NIH | NHLBI | Division of Intramural Research (DIR)
ID : HL153019
Organisme : HHS | NIH | NHLBI | Division of Intramural Research (DIR)
ID : HL170249
Organisme : HHS | NIH | NHLBI | Division of Intramural Research (DIR)
ID : HL106173
Informations de copyright
© 2024 Federation of American Societies for Experimental Biology.
Références
Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114(12):1867-1879.
Kasikara C, Doran AC, Cai B, Tabas I. The role of non-resolving inflammation in atherosclerosis. J Clin Invest. 2018;128(7):2713-2723.
Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101.
Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med. 2015;212(8):1203-1217.
Zhang MJ, Sansbury BE, Hellmann J, et al. Resolvin D2 enhances postischemic revascularization while resolving inflammation. Circulation. 2016;134(9):666-680.
Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009;461(7268):1287-1291.
Viola JR, Lemnitzer P, Jansen Y, et al. Resolving lipid mediators Maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ Res. 2016;119(9):1030-1038.
Bardin M, Pawelzik SC, Lagrange J, et al. The resolvin D2 - GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice. Biochem Pharmacol. 2022;201:115075.
Fredman G, Hellmann J, Proto JD, et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun. 2016;7:12859.
Hosseini Z, Marinello M, Decker C, et al. Resolvin D1 enhances necroptotic cell clearance through promoting macrophage fatty acid oxidation and oxidative phosphorylation. Arterioscler Thromb Vasc Biol. 2021;41(3):1062-1075.
Yurdagul A Jr, Subramanian M, Wang X, et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 2020;31(3):518-533. e10.
Kojima Y, Volkmer JP, McKenna K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536(7614):86-90.
Gerlach BD, Marinello M, Heinz J, et al. Resolvin D1 promotes the targeting and clearance of necroptotic cells. Cell Death Differ. 2019;27:525-539.
Rymut NHJ, Sadhu S, Hosseini Z, et al. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage. FASEB J. 2020;34(1):597-609.
Duan L, Zhao Y, Jia J, et al. Myeloid-restricted CD68 deficiency attenuates atherosclerosis via inhibition of ROS-MAPK-apoptosis axis. Biochim Biophys Acta Mol basis Dis. 2023;1869(5):166698.
Jablonski KA, Amici SA, Webb LM, et al. Novel markers to delineate murine M1 and M2 macrophages. PloS One. 2015;10(12):e0145342.
Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7):612-619.
Jundi B, Lee DH, Jeon H, et al. Inflammation resolution circuits are uncoupled in acute sepsis and correlate with clinical severity. JCI Insight. 2021;6(15):e148866.
Kabir I, Zhang X, Dave JM, et al. The age of bone marrow dictates the clonality of smooth muscle-derived cells in atherosclerotic plaques. Nat Aging. 2023;3(1):64-81.
Fitzgerald H, Bonin JL, Khan S, et al. Resolvin D2-GPR18 enhances bone marrow function and limits steatosis and hepatic collagen accumulation in aging. Am J Pathol. 2023;193:1953-1968.
Du W, Wong C, Song Y, et al. Age-associated vascular inflammation promotes monocytosis during atherogenesis. Aging Cell. 2016;15(4):766-777.
Wong CK, Smith CA, Sakamoto K, Kaminski N, Koff JL, Goldstein DR. Aging impairs alveolar macrophage phagocytosis and increases influenza-induced mortality in mice. J Immunol. 2017;199(3):1060-1068.
Poller WC, Nahrendorf M, Swirski FK. Hematopoiesis and cardiovascular disease. Circ Res. 2020;126(8):1061-1085.
Sharma M, Schlegel MP, Afonso MS, et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ Res. 2020;127(3):335-353.
Flores AM, Hosseini-Nassab N, Jarr KU, et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat Nanotechnol. 2020;15(2):154-161.
Console-Bram L, Brailoiu E, Brailoiu GC, Sharir H, Abood ME. Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol. 2014;171(16):3908-3917.
Leuti A, Fava M, Maccarrone M. A game of networks: do different lipids interact to orchestrate inflammatory homeostasis? Cell Chem Biol. 2023;30(12):1499-1501.
Reyes-Resina I, Navarro G, Aguinaga D, et al. Molecular and functional interaction between GPR18 and cannabinoid CB(2) G-protein-coupled receptors. Relevance in neurodegenerative diseases. Biochem Pharmacol. 2018;157:169-179.
Nicolaou A, Mauro C, Urquhart P, Marelli-Berg F. Polyunsaturated fatty acid-derived lipid mediators and T cell function. Front Immunol. 2014;5:75.
Cunningham F, Allen JE, Allen J, et al. Ensembl 2022. Nucleic Acids Res. 2022;50(D1):D988-D995.
Chiang N, Barnaeva E, Hu X, et al. Identification of Chemotype agonists for human Resolvin D1 receptor DRV1 with pro-resolving functions. Cell Chem Biol. 2019;26(2):244-254. e4.